Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Aug 29. doi: 10.1002/ana.25313. [Epub ahead of print]

PMID:
30155979
2.

Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM.

Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527. [Epub ahead of print]

PMID:
30141729
3.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

PMID:
29908077
4.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

5.

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453. doi: 10.1212/NXI.0000000000000453. eCollection 2018 May.

6.

Multiple Sclerosis: B Cells Take Center Stage.

Pröbstel AK, Hauser SL.

J Neuroophthalmol. 2018 Jun;38(2):251-258. doi: 10.1097/WNO.0000000000000642. No abstract available.

PMID:
29561328
7.

Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients.

Canto E, Isobe N, Didonna A; MS-EPIC Study Group, Hauser SL, Oksenberg JR.

J Neuroinflammation. 2018 Mar 7;15(1):72. doi: 10.1186/s12974-018-1105-9.

8.

B-Cell Therapies in Multiple Sclerosis.

Sabatino JJ Jr, Zamvil SS, Hauser SL.

Cold Spring Harb Perspect Med. 2018 Jan 22. pii: a032037. doi: 10.1101/cshperspect.a032037. [Epub ahead of print]

PMID:
29358322
9.

Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease.

Azevedo CJ, Cen SY, Khadka S, Liu S, Kornak J, Shi Y, Zheng L, Hauser SL, Pelletier D.

Ann Neurol. 2018 Feb;83(2):223-234. doi: 10.1002/ana.25150. Epub 2018 Feb 9.

PMID:
29328531
10.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407. [Epub ahead of print]

PMID:
29310490
11.

Diagnosing multiple sclerosis: art and science.

Bove RM, Hauser SL.

Lancet Neurol. 2018 Feb;17(2):109-111. doi: 10.1016/S1474-4422(17)30461-1. Epub 2017 Dec 21. No abstract available.

PMID:
29275980
12.

Ovarian aging is associated with gray matter volume and disability in women with MS.

Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A; University of California, San Francisco MS-EPIC Team,, Bacchetti P, Hauser SL, Oksenberg JR.

Neurology. 2018 Jan 16;90(3):e254-e260. doi: 10.1212/WNL.0000000000004843. Epub 2017 Dec 22.

PMID:
29273686
13.

B-cell Therapy for Multiple Sclerosis: Entering an era.

Greenfield AL, Hauser SL.

Ann Neurol. 2018 Jan;83(1):13-26. doi: 10.1002/ana.25119. Review.

PMID:
29244240
14.

Advances in Imaging Multiple Sclerosis.

Bischof A, Caverzasi E, Cordano C, Hauser SL, Henry RG.

Semin Neurol. 2017 Oct;37(5):538-545. doi: 10.1055/s-0037-1607278. Epub 2017 Dec 5. No abstract available.

PMID:
29207413
15.

Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Eggers EL, Michel BA, Wu H, Wang SZ, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E, Greenfield AL, Demuth S, Wilson MR, Henry RG, Cree BA, Hauser SL, von Büdingen HC.

JCI Insight. 2017 Nov 16;2(22). pii: 92724. doi: 10.1172/jci.insight.92724. [Epub ahead of print]

16.

Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.

Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S.

Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13.

PMID:
29030454
17.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR.

Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.

18.

Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.

Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.

19.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657. [Epub ahead of print]

PMID:
28847219
20.

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Gelfand JM, Cree BAC, Hauser SL.

Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4. Review.

PMID:
28695471
21.

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Hauser SL, Belachew S, Kappos L.

N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. No abstract available.

22.

Onset of secondary progressive MS after long-term rituximab therapy - a case report.

von Büdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL.

Ann Clin Transl Neurol. 2016 Dec 20;4(1):46-52. doi: 10.1002/acn3.377. eCollection 2017 Jan.

23.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

24.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

25.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

26.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

27.

Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.

Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R, Caillier SJ, Santaniello A, Lizée A, Himmelstein DS, Baranzini SE, Hollenbach J, Cree BA, Hauser SL, Oksenberg JR, Henry RG.

JAMA Neurol. 2016 Jul 1;73(7):795-802. doi: 10.1001/jamaneurol.2016.0980.

28.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-294. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

29.

Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.

Khankhanian P, Cozen W, Himmelstein DS, Madireddy L, Din L, van den Berg A, Matsushita T, Glaser SL, Moré JM, Smedby KE, Baranzini SE, Mack TM, Lizée A, de Sanjosé S, Gourraud PA, Nieters A, Hauser SL, Cocco P, Maynadié M, Foretová L, Staines A, Delahaye-Sourdeix M, Li D, Bhatia S, Melbye M, Onel K, Jarrett R, McKay JD, Oksenberg JR, Hjalgrim H.

Int J Epidemiol. 2016 Jun;45(3):728-40. doi: 10.1093/ije/dyv364. Epub 2016 Mar 12.

30.

A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome.

Didonna A, Isobe N, Caillier SJ, Li KH, Burlingame AL, Hauser SL, Baranzini SE, Patsopoulos NA, Oksenberg JR.

Hum Mol Genet. 2015 Dec 15;24(24):7151-8. doi: 10.1093/hmg/ddv412. Epub 2015 Oct 3.

31.

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G.

Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.

32.

Genetic contribution to multiple sclerosis risk among Ashkenazi Jews.

Khankhanian P, Matsushita T, Madireddy L, Lizée A, Din L, Moré JM, Gourraud PA, Hauser SL, Baranzini SE, Oksenberg JR.

BMC Med Genet. 2015 Jul 28;16:55. doi: 10.1186/s12881-015-0201-2.

33.

Mitochondrial DNA sequence variation in multiple sclerosis.

Tranah GJ, Santaniello A, Caillier SJ, D'Alfonso S, Martinelli Boneschi F, Hauser SL, Oksenberg JR.

Neurology. 2015 Jul 28;85(4):325-30. doi: 10.1212/WNL.0000000000001744. Epub 2015 Jul 1.

34.

Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin DS, Cree BA, Hauser SL, Henry RG.

JAMA Neurol. 2015 Aug;72(8):897-904. doi: 10.1001/jamaneurol.2015.0993.

35.

Advancing ethical neuroscience.

Hauser SL.

Ann Neurol. 2015 May;77(5):735-7. doi: 10.1002/ana.24411. Review. No abstract available.

36.

An ImmunoChip study of multiple sclerosis risk in African Americans.

Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, Moré JM, Gourraud PA, McCauley JL, Beecham AH; International Multiple Sclerosis Genetics Consortium, Piccio L, Herbert J, Khan O, Cohen J, Stone L, Santaniello A, Cree BA, Onengut-Gumuscu S, Rich SS, Hauser SL, Sawcer S, Oksenberg JR.

Brain. 2015 Jun;138(Pt 6):1518-30. doi: 10.1093/brain/awv078. Epub 2015 Mar 28.

37.

Age, gender and normalization covariates for spinal cord gray matter and total cross-sectional areas at cervical and thoracic levels: A 2D phase sensitive inversion recovery imaging study.

Papinutto N, Schlaeger R, Panara V, Zhu AH, Caverzasi E, Stern WA, Hauser SL, Henry RG.

PLoS One. 2015 Mar 17;10(3):e0118576. doi: 10.1371/journal.pone.0118576. eCollection 2015.

38.

Genetic associations with brain cortical thickness in multiple sclerosis.

Matsushita T, Madireddy L, Sprenger T, Khankhanian P, Magon S, Naegelin Y, Caverzasi E, Lindberg RL, Kappos L, Hauser SL, Oksenberg JR, Henry R, Pelletier D, Baranzini SE.

Genes Brain Behav. 2015 Feb;14(2):217-27. doi: 10.1111/gbb.12190. Epub 2015 Mar 5.

39.

Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.

Hauser SL.

JAMA. 2015 Jan 20;313(3):251-2. doi: 10.1001/jama.2014.18150. No abstract available.

PMID:
25602994
40.

High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis.

Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, Ripke S, Gusareva ES, Annese V, Hauser SL, Oksenberg JR, Thomsen I, Leslie S; International Inflammatory Bowel Disease Genetics Consortium; Australia and New Zealand IBDGC; Belgium IBD Genetics Consortium; Italian Group for IBD Genetic Consortium; NIDDK Inflammatory Bowel Disease Genetics Consortium; United Kingdom IBDGC; Wellcome Trust Case Control Consortium; Quebec IBD Genetics Consortium, Daly MJ, Van Steen K, Duerr RH, Barrett JC, McGovern DP, Schumm LP, Traherne JA, Carrington MN, Kosmoliaptsis V, Karlsen TH, Franke A, Rioux JD.

Nat Genet. 2015 Feb;47(2):172-9. doi: 10.1038/ng.3176. Epub 2015 Jan 5.

41.

2D phase-sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times.

Papinutto N, Schlaeger R, Panara V, Caverzasi E, Ahn S, Johnson KJ, Zhu AH, Stern WA, Laub G, Hauser SL, Henry RG.

J Magn Reson Imaging. 2015 Sep;42(3):698-708. doi: 10.1002/jmri.24819. Epub 2014 Dec 8.

42.

The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Hauser SL.

Mult Scler. 2015 Jan;21(1):8-21. doi: 10.1177/1352458514561911. Epub 2014 Dec 5. Review.

43.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen.

Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL.

Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14. Review.

44.

Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.

Palanichamy A, Apeltsin L, Kuo TC, Sirota M, Wang S, Pitts SJ, Sundar PD, Telman D, Zhao LZ, Derstine M, Abounasr A, Hauser SL, von Büdingen HC.

Sci Transl Med. 2014 Aug 6;6(248):248ra106. doi: 10.1126/scitranslmed.3008930.

45.

Spinal cord gray matter atrophy correlates with multiple sclerosis disability.

Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG.

Ann Neurol. 2014 Oct;76(4):568-80. doi: 10.1002/ana.24241. Epub 2014 Aug 21.

46.

In vivo evidence of glutamate toxicity in multiple sclerosis.

Azevedo CJ, Kornak J, Chu P, Sampat M, Okuda DT, Cree BA, Nelson SJ, Hauser SL, Pelletier D.

Ann Neurol. 2014 Aug;76(2):269-78. doi: 10.1002/ana.24202. Epub 2014 Jul 9.

47.

Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.

Mei F, Fancy SPJ, Shen YA, Niu J, Zhao C, Presley B, Miao E, Lee S, Mayoral SR, Redmond SA, Etxeberria A, Xiao L, Franklin RJM, Green A, Hauser SL, Chan JR.

Nat Med. 2014 Aug;20(8):954-960. doi: 10.1038/nm.3618. Epub 2014 Jul 6.

48.

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC.

J Immunol. 2014 Jul 15;193(2):580-586. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.

49.

Neurology: violence at home.

Hauser SL, Johnston SC.

Ann Neurol. 2013 Aug;74(2):A5-6. doi: 10.1002/ana.23979. No abstract available.

PMID:
24902528
50.

Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis.

Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree BA, Sampat M, Hauser SL, Nelson SJ, Pelletier D.

JAMA Neurol. 2014 Jul 1;71(7):840-7. doi: 10.1001/jamaneurol.2014.895.

PMID:
24839987

Supplemental Content

Loading ...
Support Center